FLAG方案治疗难治/复发急性髓细胞性白血病的疗效观察

Effects of FLAG Regimen in Treatment of Refractory or Relapsed Acute Myeloid Leukemia

为了探讨FLAG方案治疗难治和复发急性髓细胞性白血病(refractoryandrelapsedacutemyeloidleukemia)的疗效,本研究采用FLAG方案(氟达拉宾50mg,静脉点滴,30分滴完,第1-5天;阿糖胞苷1000mg/m2,静脉点滴,第1-5天;GCSF150-300μg皮下注射第0-5天)治疗27例难治和复发急性髓细胞性白血病,其中难治性AML10例,复发AML17例。结果表明:27例患者中,13例难治和复发AML达完全缓解(CR率48.2%),4例达部分缓解(PR率14.8%),总有效率63.0%。CR的患者中有3例已行异基因造血干细胞移植,目前3例均处于无病存活状况,其中存活最长的20个月,仍处于CR期。毒副作用主要为骨髓抑制、消化道症状、轻度肝功异常。结论:FLAG方案对部分难治和复发AML仍有效,毒副作用可以耐受,可用于治疗对其他化疗方案无效的难治和复发AML,并为患者行造血干细胞移植创造机会。

In order to evaluate the effects of FLAG regimen in treatment of refractory and relapsed acute myeloid leukemia (AML), 27 patients with refractory or relapsed acute myeloid leukemia (10 refractory AML patients,17 relapsed AML patients) were treated with FLAG regimen. The results show that the rate of complete remission was 48.2% (13/27) , the rate of partial remission was 14.8% (4/27) , and the overall response rate was 63.0%. Main toxicities were gastrointestinal side effectes, myelosupression and neutropenia. It is concluded that FLAG regimen can be employed in treatment of the refractory or relapsed patients who were not respond to other regimen, and the regiment was safe.